Welcome to our dedicated page for Cosciens Biopharma SEC filings (Ticker: CSCIF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
COSCIENS Biopharma Inc (CSCIF) is described as a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions. While no SEC filings are listed here, investors often look to regulatory documents such as annual and quarterly reports and registration statements to better understand companies like COSCIENS that operate in pharmaceutical diagnostics and natural active ingredients.
For COSCIENS, key areas of interest in formal filings typically include disclosures related to its lead pharmaceutical product Macrilen (macimorelin), which is characterized as a ghrelin agonist and the first and only FDA and EMA approved oral test for diagnosing Adult Growth Hormone Deficiency (AGHD). Filings can also provide detail on licensing or distribution arrangements, such as the exclusive distribution agreement between COSCIENS’ subsidiary Aeterna Zentaris GmbH and Wuzhou Drug International Trading Limited for Macrilen in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan.
In addition, regulatory documents often describe business segments and technologies. For COSCIENS, this includes its natural active ingredient business, which leverages proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients used in skincare brands worldwide. Such filings can help clarify how these activities contribute to the overall life sciences portfolio.
On this page, Stock Titan provides structured access to COSCIENS-related regulatory information when available, along with AI-powered tools that summarize long-form filings, highlight key sections, and make it easier to identify disclosures related to pharmaceutical diagnostics, distribution agreements, and natural ingredient technologies.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.